Where Anti-ADRA2A (α2B adrenergic receptor) is reported
Also listed as: GPCR autoantibody
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| PACVS | ↓ reduced | healthy controls (inverse with symptoms) | Negatively associated with brain fog | Mantovani et al. 2024 |
Frequently asked questions
In which conditions is Anti-ADRA2A (α2B adrenergic receptor) altered?
In the OSMF atlas Anti-ADRA2A (α2B adrenergic receptor) is reported in PACVS. It is reduced in 1 across 1 entries.
Is there a standard clinical test for Anti-ADRA2A (α2B adrenergic receptor)?
The atlas entries for Anti-ADRA2A (α2B adrenergic receptor) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal Anti-ADRA2A (α2B adrenergic receptor) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-30 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.